Concepedia

Publication | Open Access

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT

DOIFull Paper Access

173

Citations

29

References

2023

Year

Kimball A. Johnson, Nancy Martin, Rossella E. Nappi, Genevieve Neal-Perry, Marla Shapiro, Petra Stute, Rebecca C. Thurston, Wendy Wolfman, Marci English, Catherine Franklin,
The Journal of Clinical Endocrinology & Metabolism

Abstract

Daily fezolinetant 30 and 45 mg were efficacious and well tolerated for treating moderate to severe VMS associated with menopause.

References

YearCitations

Page 1